{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T00:19:00Z","timestamp":1793319540177,"version":"4.5.0"},"reference-count":25,"publisher":"American Society of Hematology","issue":"3","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,2,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Immune thrombotic thrombocytopenic purpura (iTTP) is a life-threatening thrombotic microangiopathy. It is caused by a severe ADAMTS13 (a disintegrin and metalloprotease with thrombospondin type 1 motifs, 13) deficiency due to circulating autoantibodies, and is associated with significant morbidity and mortality. Current treatment options include plasma exchange, immunosuppression, and caplacizumab. When remission is achieved, the risk of relapse is high, especially in patients with persistent ADAMTS13 deficiency. We report the eradication of persistent ADAMTS13 inhibitory autoantibodies and restoration of normal ADAMTS13 activity using the anti-CD38 antibody daratumumab in two patients with iTTP. One patient had a frequently relapsing course, and the other a treatment-refractory first episode. There were no relevant adverse drug reactions.<\/jats:p>","DOI":"10.1182\/bloodadvances.2021005124","type":"journal-article","created":{"date-parts":[[2021,9,22]],"date-time":"2021-09-22T16:09:41Z","timestamp":1632326981000},"page":"993-997","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":43,"title":["Daratumumab for immune thrombotic thrombocytopenic purpura"],"prefix":"10.1182","volume":"6","author":[{"given":"Jana","family":"van den Berg","sequence":"first","affiliation":[{"name":"Division of Hematology, University Hospital Basel, Basel, Switzerland;"},{"name":"Regional Blood Transfusion Service, Swiss Red Cross, Basel, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1300-7135","authenticated-orcid":false,"given":"Johanna A.","family":"Kremer Hovinga","sequence":"additional","affiliation":[{"name":"Central Hematology Laboratory, Department of Hematology, Inselspital, University of Bern, Bern, Switzerland; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Pfleger","sequence":"additional","affiliation":[{"name":"Division of Hematology, University Hospital Basel, Basel, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inga","family":"Hegemann","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology and Hematology, University Hospital Z\u00fcrich, Z\u00fcrich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregor","family":"Stehle","sequence":"additional","affiliation":[{"name":"Division of Hematology, University Hospital Basel, Basel, Switzerland;"},{"name":"Regional Blood Transfusion Service, Swiss Red Cross, Basel, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Holbro","sequence":"additional","affiliation":[{"name":"Division of Hematology, University Hospital Basel, Basel, Switzerland;"},{"name":"Regional Blood Transfusion Service, Swiss Red Cross, Basel, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan-Dirk","family":"Studt","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology and Hematology, University Hospital Z\u00fcrich, Z\u00fcrich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2022,2,4]]},"reference":[{"issue":"21","key":"2022020416231641600_B1","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1182\/blood-2016-10-709857","article-title":"Thrombotic thrombocytopenic purpura","volume":"129","author":"Joly","year":"2017","journal-title":"Blood."},{"issue":"5","key":"2022020416231641600_B2","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1182\/blood.2019000954","article-title":"How targeted therapy disrupts the treatment paradigm for acquired TTP: the risks, benefits, and unknowns","volume":"134","author":"Mazepa","year":"2019","journal-title":"Blood."},{"issue":"14","key":"2022020416231641600_B3","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1182\/blood.2020009150","article-title":"Redefining outcomes in immune TTP: an international working group consensus report","volume":"137","author":"Cuker","year":"2021","journal-title":"Blood."},{"issue":"8","key":"2022020416231641600_B4","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1182\/blood-2009-09-243790","article-title":"Survival and relapse in patients with thrombotic thrombocytopenic purpura","volume":"115","author":"Kremer Hovinga","year":"2010","journal-title":"Blood."},{"issue":"6","key":"2022020416231641600_B5","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1505533","article-title":"Caplacizumab for acquired thrombotic thrombocytopenic purpura","volume":"374","author":"Peyvandi","year":"2016","journal-title":"N Engl J Med."},{"issue":"4","key":"2022020416231641600_B6","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa1806311","article-title":"Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura","volume":"380","author":"Scully","year":"2019","journal-title":"N Engl J Med."},{"issue":"20","key":"2022020416231641600_B7","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1182\/blood-2018-04-840090","article-title":"Preemptive rituximab prevents long-term relapses in immune-mediated thrombotic thrombocytopenic purpura","volume":"132","author":"Jestin","year":"2018","journal-title":"Blood."},{"key":"2022020416231641600_B8","doi-asserted-by":"crossref","first-page":"1076029618825309","DOI":"10.1177\/1076029618825309","article-title":"Comparison of the long-term remission of rituximab and conventional treatment for acquired thrombotic thrombocytopenic purpura: a systematic review and meta-analysis","volume":"25","author":"Owattanapanich","year":"2019","journal-title":"Clin Appl Thromb Hemost."},{"issue":"1","key":"2022020416231641600_B9","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1111\/bjh.17170","article-title":"Intensive rituximab regimen in immune-mediated thrombotic thrombocytopenic purpura can circumvent unresponsiveness to standard rituximab treatment","volume":"192","author":"Barba","year":"2021","journal-title":"Br J Haematol."},{"issue":"1","key":"2022020416231641600_B10","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1056\/NEJMc1714146","article-title":"Ofatumumab for TTP in a patient with anaphylaxis associated with rituximab","volume":"378","author":"Crowley","year":"2018","journal-title":"N Engl J Med."},{"issue":"1","key":"2022020416231641600_B11","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1056\/NEJMc1213206","article-title":"ADAMTS13 antibody depletion by bortezomib in thrombotic thrombocytopenic purpura","volume":"368","author":"Shortt","year":"2013","journal-title":"N Engl J Med."},{"issue":"1","key":"2022020416231641600_B12","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/j.1365-2141.2006.06384.x","article-title":"An evaluation of ciclosporin and corticosteroids individually as adjuncts to plasma exchange in the treatment of thrombotic thrombocytopenic purpura","volume":"136","author":"Cataland","year":"2007","journal-title":"Br J Haematol."},{"issue":"11","key":"2022020416231641600_B13","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1111\/j.1537-2995.2012.03578.x","article-title":"Splenectomy and\/or cyclophosphamide as salvage therapies in thrombotic thrombocytopenic purpura: the French TMA Reference Center experience","volume":"52","author":"Beloncle","year":"2012","journal-title":"Transfusion."},{"issue":"23","key":"2022020416231641600_B14","doi-asserted-by":"crossref","first-page":"3469","DOI":"10.1182\/blood-2014-04-561142","article-title":"The splenic autoimmune response to ADAMTS13 in thrombotic thrombocytopenic purpura contains recurrent antigen-binding CDR3 motifs","volume":"124","author":"Schaller","year":"2014","journal-title":"Blood."},{"issue":"1","key":"2022020416231641600_B15","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1172\/JCI65689","article-title":"B cell depletion in immune thrombocytopenia reveals splenic long-lived plasma cells","volume":"123","author":"Mah\u00e9vas","year":"2013","journal-title":"J Clin Invest."},{"issue":"589","key":"2022020416231641600_B16","doi-asserted-by":"crossref","first-page":"eabc3961","DOI":"10.1126\/scitranslmed.abc3961","article-title":"Rituximab-resistant splenic memory B cells and newly engaged naive B cells fuel relapses in patients with immune thrombocytopenia","volume":"13","author":"Crickx","year":"2021","journal-title":"Sci Transl Med."},{"issue":"6","key":"2022020416231641600_B17","doi-asserted-by":"crossref","first-page":"e447","DOI":"10.1016\/S2352-3026(20)30081-8","article-title":"Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials","volume":"7","author":"Usmani","year":"2020","journal-title":"Lancet Haematol."},{"key":"2022020416231641600_B18","doi-asserted-by":"crossref","first-page":"649441","DOI":"10.3389\/fimmu.2021.649441","article-title":"The immunomodulatory effect and clinical efficacy of daratumumab in a patient with cold agglutinin disease","volume":"12","author":"Zaninoni","year":"2021","journal-title":"Front Immunol."},{"issue":"12","key":"2022020416231641600_B19","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1056\/NEJMoa2023325","article-title":"Targeting CD38 with daratumumab in refractory systemic lupus erythematosus","volume":"383","author":"Ostendorf","year":"2020","journal-title":"N Engl J Med."},{"key":"2022020416231641600_B20","doi-asserted-by":"crossref","first-page":"602102","DOI":"10.3389\/fneur.2020.602102","article-title":"Case report: daratumumab in a patient with severe refractory anti-NMDA receptor encephalitis","volume":"11","author":"Ratuszny","year":"2020","journal-title":"Front Neurol."},{"issue":"3","key":"2022020416231641600_B21","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1159\/000503951","article-title":"Daratumumab for treatment of antibody-mediated rejection after ABO-incompatible kidney transplantation","volume":"9","author":"Spica","year":"2019","journal-title":"Case Rep Nephrol Dial."},{"issue":"19","key":"2022020416231641600_B22","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1056\/NEJMoa1807438","article-title":"Daratumumab for delayed red-cell engraftment after allogeneic transplantation","volume":"379","author":"Chapuy","year":"2018","journal-title":"N Engl J Med."},{"key":"2022020416231641600_B23","doi-asserted-by":"crossref","first-page":"946","DOI":"10.3389\/fimmu.2020.00946","article-title":"The changing landscape of autoimmune hemolytic anemia","volume":"11","author":"Barcellini","year":"2020","journal-title":"Front Immunol."},{"issue":"13","key":"2022020416231641600_B24","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1182\/bloodadvances.2020001987","article-title":"ADAMTS13 and VWF activities guide individualized caplacizumab treatment in patients with aTTP","volume":"4","author":"V\u00f6lker","year":"2020","journal-title":"Blood Adv."},{"issue":"5","key":"2022020416231641600_B25","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1111\/j.1538-7836.2006.01904.x","article-title":"Measurement of ADAMTS-13 activity in plasma by the FRETS-VWF73 assay: comparison with other assay methods","volume":"4","author":"Kremer Hovinga","year":"2006","journal-title":"J Thromb Haemost."}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/3\/993\/1867722\/advancesadv2021005124.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/3\/993\/1867722\/advancesadv2021005124.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,4]],"date-time":"2022-02-04T11:57:42Z","timestamp":1643975862000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/6\/3\/993\/476991\/Daratumumab-for-immune-thrombotic-thrombocytopenic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,4]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,2,8]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2021005124","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,4]]}}}